Galmed Pharmaceuticals (GLMD) Stock Forecast, Price & News

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

Is Galmed Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Galmed Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares.
View analyst ratings for Galmed Pharmaceuticals or view top-rated stocks.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 23,200 shares, a decrease of 27.3% from the April 30th total of 31,900 shares. Based on an average daily volume of 92,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the shares of the company are sold short.
View Galmed Pharmaceuticals' Short Interest.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Galmed Pharmaceuticals.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) released its earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.08.
View Galmed Pharmaceuticals' earnings history.

What price target have analysts set for GLMD?

2 Wall Street analysts have issued 1 year price objectives for Galmed Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Galmed Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 861.2% from the stock's current price.
View analysts' price targets for Galmed Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the following people:

• Mr. Allen Baharaff, Co-Founder, Pres, CEO & Chairman (Age 57, Pay $766.58k)
• Mr. Guy Nehemya, Chief Operating Officer (Age 37, Pay $167.54k)
• Mr. Yohai Stenzler CPA, Chief Accounting Officer (Age 39, Pay $167.26k)
• Dr. Liat Hayardeny, Chief Scientific Officer (Age 55, Pay $215.45k)
• Dr. Tali Gorfine, Medical Consultant (Age 52, Pay $202.76k)
• Mr. Doron Cohen, Chief Financial Officer
• Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 39)
• Ms. Shani Ganon, HR Mang.
• Mr. Niv Alon, Head of PMO
• Ms. Topaz Falkoviz Arbel, Corp. Sec.

Who are some of Galmed Pharmaceuticals' key competitors?

Some companies that are related to Galmed Pharmaceuticals include Reneo Pharmaceuticals (RPHM), BeyondSpring (BYSI), LifeVantage (LFVN), Athersys (ATHX), Eledon Pharmaceuticals (ELDN), Novan (NOVN), Corvus Pharmaceuticals (CRVS), Biofrontera (BFRI), Synaptogenix (SNPX), Connect Biopharma (CNTB), Larimar Therapeutics (LRMR), ProQR Therapeutics (PRQR), vTv Therapeutics (VTVT), Rezolute (RZLT) and Galera Therapeutics (GRTX).
View all of GLMD's competitors.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (1.03%), Raymond James Financial Services Advisors Inc. (0.25%), Cambridge Investment Research Advisors Inc. (0.10%) and Concourse Financial Group Securities Inc. (0.00%).

Which institutional investors are selling Galmed Pharmaceuticals stock?

GLMD stock was sold by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC.

Which institutional investors are buying Galmed Pharmaceuticals stock?

GLMD stock was purchased by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc., and Cambridge Investment Research Advisors Inc..

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $0.52.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals has a market capitalization of $13.05 million. The biopharmaceutical company earns $-32.47 million in net income (profit) each year or ($1.180010) on an earnings per share basis.

How many employees does Galmed Pharmaceuticals have?

Galmed Pharmaceuticals employs 18 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is www.galmedpharma.com.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at [email protected], or via fax at 972-3693-8447.